ADMA Biologics ADMA Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from ADMA Biologics’s reported figures.
Based on trailing twelve months.
The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about ADMA Biologics's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ADMA Biologics's return on equity?
- ADMA Biologics (ADMA) reported return on equity of 43.3% in Q1 2026.
- How has ADMA Biologics's return on equity changed year-over-year?
- ADMA Biologics's return on equity decreased by 44.8% year-over-year, from 78.5% to 43.3%.
- What is the long-term trend for ADMA Biologics's return on equity?
- Over 5 years (2020 to 2025), ADMA Biologics's return on equity has grown at a -23.1% compound annual growth rate (CAGR), from -132.4% to 35.6%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.